Acacia Barium Carbonate Borage Oil Fucus Vesiculos

證據等級: L5

預測適應症: 0 個

Multi-Component Thyroid Formulation: Insufficient Evidence for Drug Repurposing Evaluation

One-Sentence Summary

This submission contains a complex 12-ingredient mixture — including ACACIA, BARIUM CARBONATE, BORAGE OIL, FUCUS VESICULOSUS, HYDROFLUORIC ACID, IODINE, OLIVE OIL, OYSTER SHELL CALCIUM CARBONATE, PULSATILLA PRATENSIS WHOLE, SESAME OIL, SODIUM CHLORIDE, and THYROID — likely representing a homeopathic or naturopathic thyroid-support preparation. The TxGNN model returned no predicted indications for this compound, and the product has no regulatory approvals in the US market. Without a recognized single active ingredient, a DrugBank identifier, or any clinical evidence, this candidate cannot proceed through standard repurposing evaluation at this time.

Quick Overview

Item	Content
Original Indication	No approved indication on record
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model could not generate prediction)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why the Prediction Could Not Be Generated

This submission presents a fundamental structural challenge: the “drug” field contains twelve heterogeneous ingredients rather than a single active pharmaceutical ingredient (API). The TxGNN knowledge graph is anchored to individual DrugBank entities mapped to specific molecular mechanisms; a composite entry of this type cannot be resolved to a single node in the knowledge graph.

Several components in this formulation are of particular concern from a scientific standpoint. Barium carbonate is an acutely toxic heavy metal salt with no established therapeutic role. Hydrofluoric acid is a highly corrosive industrial chemical. The presence of these alongside recognized dietary and botanical ingredients (iodine, olive oil, sesame oil, borage oil, sodium chloride, calcium carbonate) is inconsistent with a standard pharmaceutical product and more consistent with a homeopathic dilution formula, where individual ingredients are nominally listed but present at sub-pharmacological concentrations.

Without a DrugBank ID, a defined mechanism of action, or a primary active ingredient, neither the knowledge-graph method nor the deep-learning method can generate meaningful repurposing predictions.

Conclusion and Next Steps

Decision: Hold

Rationale: The submission cannot be evaluated under the standard TxGNN drug repurposing framework because no single mappable active ingredient exists, the TxGNN model returned zero predicted indications, the product has no US regulatory history, and multiple component substances carry significant safety concerns at pharmacological doses.

To proceed, the following is needed:

Identify the primary active ingredient: Determine which single component (most likely IODINE or THYROID extract, given the formulation profile) is intended as the API, and resubmit under that compound’s INN and DrugBank ID.
Clarify product classification: Confirm whether this is a homeopathic product, a dietary supplement, or a pharmaceutical. Each pathway has different regulatory and evidence requirements.
Resolve safety concerns: BARIUM CARBONATE and HYDROFLUORIC ACID require explicit toxicological justification and concentration disclosure before any evaluation can proceed. These are blocking issues.
Obtain package insert or product monograph: Required to establish original indication, dosing rationale, and contraindication profile.
Re-run TxGNN against the isolated API: Once a single DrugBank-mappable ingredient is identified, the prediction pipeline can be executed normally.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.